Introduction
Immune checkpoint inhibitors are a recently developed group of anticancer agents that use the body's immune system to eradicate cancerous cells, in contrast to smallmolecule drugs and monoclonal antibodies that target cancer cells themselves. The immune system is able to recognize and destroy cancerous cells, but this mechanism can be suppressed through immune evasion by the tumor. Immune checkpoint inhibitors remove this suppression by targeting the proteins involved, thus allowing the immune system to eliminate the tumor.
This mechanism of action suggests that the immune checkpoint inhibitors may provide particular benefit as adjuvant therapies, 2, 3 which are administered after the primary treatment in order to lower the risk that the cancer will come back. 1 However, immune checkpoint inhibitors have to date been approved for the treatment of metastatic cancer, where the aim of treatment is typically to extend life rather than provide a cure; recently approved products include ipilimumab (Yervoy; Bristol-Myers Squibb) and pembrolizumab (Keytruda; Merck) for advanced melanoma, and nivolumab (Opdivo; Bristol-Myers Squibb) for advanced non-small cell lung cancer. Given the high cost of these therapies, we wanted to identify the likely challenges for the pricing and reimbursement of immune checkpoint inhibitors as adjuvants.
Objectives
• To identify evidence on the use of immune checkpoint inhibitors in the adjuvant setting • To identify the challenges for manufacturers and payers in the pricing and reimbursement of immune checkpoint inhibitors in the adjuvant setting
Development of immune checkpoint inhibitors in the adjuvant setting
We searched clinicaltrials.gov in January 2015, using a list of immune checkpoint inhibitors known to be in clinical development, and repeated the search in March. These agents are being evaluated as adjuvant therapies for a variety of malignancies, but the lead indication is clearly melanoma. An application for US regulatory approval of adjuvant ipilimumab was submitted in March 2015. This indication and agent will therefore be a test case that will provide insight into agencies' requirements for the pricing and reimbursement of immune-checkpoint inhibitors as adjuvants.
Two Phase 3 trials in this indication were registered between the initial search in January 2015 and the second search in March -a head-to-head trial of nivolumab versus ipilimumab (NCT02388906) and a placebo-controlled trial of pembrolizumab (NCT02362594) -indicating that this is a rapidly developing area of use for these agents. The existence of several competing agents in this indication will add a further consideration to planning by manufacturers for pricing and reimbursement negotiations.
Previous HTAs of adjuvants
We identified published health technology assessments (HTAs) of adjuvant cancer therapies by NICE (England and Wales), the SMC (Scotland), and PBAC (Australia); these agencies were chosen as examples because they consider both clinical and economic evidence, and provide comprehensive rationales for their decisions. Tolerability is a concern: agencies have questioned whether the clinical benefit outweighs the side-effects.
The risk-benefit and cost-benefit ratios vary according to the patient's risk of relapse. Recommendations have included restriction to high-risk patients. All appraisals but one led to a positive final decision. Few of the products reached the upper limit for acceptable incremental cost-effectiveness ratios (ICERs); however, imatinib was initially rejected by all three agencies on cost-effectiveness grounds. In each case, the drug was accepted after a resubmission despite the high ICER, which suggests that agencies may accept ICERs for adjuvant treatments that are close to those usually associated with life-extending treatments for advanced cancer.
The appraisal documents were reviewed to identify the challenges associated with adjuvant therapies.
Future challenges for immune checkpoint inhibitors in the adjuvant setting
How can the desire to provide patients with potent, potentially curative, therapies be balanced against uncertainty about their long-term effectiveness?
• Manufacturers will need to consider the need for longer-term outcomes when planning their trial programs.
• One option is to ensure trials are appropriately powered and of sufficient duration to provide mature survival data when required for negotiations (even if post-licensing), or at least to reduce uncertainty in estimates. • Alternatively, extrapolation will be needed. The methodology for extrapolating results will need to be agreed in consultation with payers. This is particularly important given the additional uncertainty associated with a new type of therapy.
• Regulators and payers may consider conditional approval and uptake in order to provide access to patients despite the uncertainty about long-term clinical effectiveness.
What is the appropriate target population?
• Patients' risk status affects the balance between efficacy and safety, and between efficacy and cost of treatment. • Manufacturers will need to consider patient subgroups carefully and incorporate them into trial planning. • These subgroups must be clearly identifiable in clinical practice.
What is the appropriate duration of treatment?
• A longer duration of treatment may reduce the risk of relapse but increase the risk of adverse effects and the cost of treatment. • Payers will expect clear stopping rules; the trial program must establish the optimal stopping rules from a safety and an economic perspective.
How should concerns about long-term safety be addressed?
• Long-term safety issues may not be apparent until after many years of widespread use.
• Manufacturers, regulators, and healthcare providers will need to work together to investigate and manage these risks.
How should long-term prevention of disease recurrence, and even cure, be valued?
• Increasing the chance of cure, and hence the chance for a patient to have a diseasefree life, is a strong, patient-centered value driver; however, it has not been assigned additional value in HTA in the same way as, for example, the extension of survival at the end of life. • Manufacturers will need to be creative in their approach to capturing this benefit in a way that can be demonstrated to decision-makers. 
